ArticleMolecular biotechnology2026
Tectochrysin Attenuates the Chemoresistance of Hepatocellular Carcinoma Cells to Sorafenib by Inhibiting the PI3K/AKT Signaling Pathway and ABCG2 Expression.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A flavonoid compound known as tectochrysin (TEC), which is extracted from Alpinia Oxyphylla Miq, possesses anti-cancer properties across a range of cancer types. This study aims to investigate its role in reversing sorafenib (SR) resistance in hepatocellular carcinoma (HCC) and the underlying mechanism. SR-resistant HCC cells (Huh7 SR and HCCLM3 SR) were generated through long-term induction of parental cells with escalating doses of SR. Cell viability was evaluated by CCK-8 assays. Cell proliferation was assessed by colony formation assays. Flow cytometry analysis was used to analyze cell apoptosis and cell cycle. Transwell and wound healing assays were applied to detect cell invasion and migration, respectively. Immunofluorescence staining was used to detect ABCG2 expression and p-AKT nuclear translocation. Cellular thermal shift assay (CETSA) and drug affinity responsive target stability (DARTS) assay were performed to validate the binding of TEC to PI3K and ABCG2 protein. HCC cell-derived xenograft models were used to confirm the anti-cancer effects of TEC in vivo. Western blot analysis was employed to detect the levels of proteins related to apoptosis, epithelial-mesenchymal transition (EMT), and the PI3K/AKT/ABCG2 pathway in cells and tissues. TEC significantly augmented the sensitivity of SR-resistant HCC cell lines to SR, synergistically inhibiting cell proliferation and colony formation. Combination treatment with TEC and SR potently induced G1/S cell cycle arrest and promoted apoptosis, accompanied by regulation of Bcl-2, Bax, C-PARP, C-caspase-3. Furthermore, TEC combined with SR effectively suppressed cell migration, invasion, and EMT, upregulating E-cadherin while downregulating N-cadherin and Vimentin. Mechanistically, TEC combined with SR exerted inhibitory effects on the PI3K/AKT/ABCG2 signaling. Evidence for this includes reduced expression of ABCG2, p-AKT, and p-PI3K, compromised ABCG2 expression, and attenuated nuclear translocation of p-AKT. In vivo, TEC and SR synergistically inhibited the growth of xenograft tumors derived from SR-resistant cells and reduced the expression of Ki67, ABCG2, and PI3K/AKT pathway proteins. Our study illustrates that TEC alleviates SR-associated chemoresistance in HCC cells by restraining activation of the PI3K/AKT signaling and inhibiting ABCG2 expression. This finding identifies TEC as a potential candidate to tackle SR resistance in HCC.
Indexed as
Identifiers
42599637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.